Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7688291rdf:typepubmed:Citationlld:pubmed
pubmed-article:7688291lifeskim:mentionsumls-concept:C0205653lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C0037663lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C0122592lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C0021665lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:7688291lifeskim:mentionsumls-concept:C1335671lld:lifeskim
pubmed-article:7688291pubmed:issue2lld:pubmed
pubmed-article:7688291pubmed:dateCreated1993-9-3lld:pubmed
pubmed-article:7688291pubmed:abstractTextIn the adult rat, expression of the liver GH receptor, insulin-like growth factor-I (IGF-I), and IGF-I-binding protein-3 (IGFBP-3) genes has been shown to be under GH control. Additionally, hypophysectomy and GH treatment have a differential effect on the relative abundance of liver IGF-I mRNA variants in adult rats. To further elucidate the time of appearance and the extent of GH control of liver GH receptor, IGF-I, and IGFBP-3 gene expression, we studied the effect of hypophysectomy and GH and IGF-I treatment in juvenile rats. Male Wistar rats were hypophysectomized (Hx) on postnatal day 26 and received twice daily sc injections of saline, recombinant human GH (2.5 U/kg.day), or recombinant human IGF-I (500 micrograms/kg.day) for 7 days. Sham-operated rats received the same treatment. Hx animals also received T4 (20 micrograms/kg.day). In Hx animals, there was a significant reduction in body weight (69.8 +/- 6.6 vs. 100.4 +/- 5.4 g; P < 0.001). GH, but not IGF-I, treatment increased body weight (79.6 +/- 9.6 g after GH vs. 69.8 +/- 6.6 g before GH; P < 0.05). GH treatment partially maintained liver, kidney, and lung weights in Hx animals and increased them in intact animals, whereas IGF-I treatment did so only in the lungs of intact and Hx animals. Serum GH and IGF-I levels were markedly reduced in Hx animals compared with those in intact controls, and GH treatment maintained, albeit partially, circulating IGF-I levels compared with those in saline-treated Hx animals. IGF-I mRNA levels were markedly reduced in Hx liver (25.0 +/- 5.4%; P < 0.001 compared with intact controls). GH treatment for 7 days increased IGF-I mRNA levels by 4.8-fold over the levels in 9-day Hx animals and increased IGF-I mRNA levels by 2.2-fold in control rats. Hypophysectomy decreased exon 2-containing transcripts by 7.0-fold and exon 1-containing transcripts by 4.1-fold. GH treatment, however, affected both exon 1- and exon 2-containing transcripts similarly. Hepatic IGFBP-3 mRNA levels were reduced in Hx (53.2 +/- 1.8%; P < 0.01 compared with intact controls) and IGF-treated Hx animals, but were not decreased in Hx GH-treated animals (100.6 +/- 9.5). No changes in GH receptor or GH-binding protein mRNA levels were caused by Hx, GH, or IGF-I treatment.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:7688291pubmed:languageenglld:pubmed
pubmed-article:7688291pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7688291pubmed:statusMEDLINElld:pubmed
pubmed-article:7688291pubmed:monthAuglld:pubmed
pubmed-article:7688291pubmed:issn0013-7227lld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:LaronZZlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:LeRoithDDlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:KochIIlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:EshetRRlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:RobertsC...lld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:StannardBBlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:CassorlaFFlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:GiladIIlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:DomenéHHlld:pubmed
pubmed-article:7688291pubmed:authorpubmed-author:Krishnamurthi...lld:pubmed
pubmed-article:7688291pubmed:issnTypePrintlld:pubmed
pubmed-article:7688291pubmed:volume133lld:pubmed
pubmed-article:7688291pubmed:ownerNLMlld:pubmed
pubmed-article:7688291pubmed:authorsCompleteYlld:pubmed
pubmed-article:7688291pubmed:pagination675-82lld:pubmed
pubmed-article:7688291pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:meshHeadingpubmed-meshheading:7688291-...lld:pubmed
pubmed-article:7688291pubmed:year1993lld:pubmed
pubmed-article:7688291pubmed:articleTitleGrowth hormone (GH) stimulates insulin-like growth factor-I (IGF-I) and IGF-I-binding protein-3, but not GH receptor gene expression in livers of juvenile rats.lld:pubmed
pubmed-article:7688291pubmed:affiliationDiabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.lld:pubmed
pubmed-article:7688291pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7688291lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7688291lld:pubmed